[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuihwqzy-g_6U_8aL3qpO7IalTPgHy_Rpi2n_OpzwYcc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Avid Radiopharmaceuticals",[4],54,false,0,10,6830,2,[13,16,19,22,25,27,29,31],{"name":14,"count":15},"Alzheimer's Disease",27,{"name":17,"count":18},"Alzheimer Disease",12,{"name":20,"count":21},"Mild Cognitive Impairment",6,{"name":23,"count":24},"Parkinson's Disease",3,{"name":26,"count":24},"Alzheimers Disease",{"name":28,"count":11},"Type 2 Diabetes",{"name":30,"count":11},"Traumatic Brain Injury",{"name":32,"count":11},"Frontotemporal Dementia",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,68,255,312,336,354,378,403,421,439,462,484,509,535,703,760],{"intervention":43,"totalTrials":44,"cells":45},"Florbetapir F18",1,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":66},{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[],{"trials":55,"activeCount":8},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"NCT01946243","The Feasibility of Florbetapir Quantitation","COMPLETED",[39],"2014-04","2013-08",96,[26],[43],{"trials":67,"activeCount":8},[],{"intervention":69,"totalTrials":70,"cells":71},"Flortaucipir F18",18,{"EARLY_PHASE1":72,"PHASE1":84,"PHASE2":161,"PHASE3":220,"PHASE4":251,"NA":253},{"trials":73,"activeCount":8},[74],{"nctId":75,"briefTitle":76,"status":59,"phases":77,"primaryCompletion":78,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":82},"NCT04474405","Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects",[35],"2013-12-09","2013-08-16",36,[17],[69,83],"Florbetapir F 18",{"trials":85,"activeCount":8},[86,94,103,114,123,132,144,152],{"nctId":87,"briefTitle":88,"status":59,"phases":89,"primaryCompletion":90,"completion":90,"start":91,"enrollment":24,"conditions":92,"interventions":93},"NCT02350634","18F-AV-1451 High Resolution Autopsy Study",[36],"2017-06-16","2016-11-26",[14],[69],{"nctId":95,"briefTitle":96,"status":59,"phases":97,"primaryCompletion":98,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":102},"NCT04468347","Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease",[36],"2018-02","2014-10",89,[17,20],[69],{"nctId":104,"briefTitle":105,"status":59,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":113},"NCT02167594","Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers",[36],"2016-07-11","2014-08-12",29,[111,112],"Progressive Supranuclear Palsy","Corticobasal Degeneration",[69],{"nctId":115,"briefTitle":116,"status":59,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"NCT03040713","Flortaucipir PET Imaging in Subjects With FTD",[36],"2018-10-24","2017-04-11",16,[32],[69],{"nctId":124,"briefTitle":125,"status":59,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},"NCT02278354","Tau Imaging in Professional Fighters",[36],"2017-02-03","2015-02-18",35,[14],[69],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT03052972","Flortaucipir 18F PET Imaging in BIOCARD Study","TERMINATED",[36],"2018-08-14","2018-08-17","2017-03-23",23,[142],"Cognitive Decline",[69],{"nctId":145,"briefTitle":146,"status":59,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":21,"conditions":150,"interventions":151},"NCT02336360","Augmenting Flortaucipir Dosimetry Estimates",[36],"2015-06","2015-01",[14],[69],{"nctId":153,"briefTitle":154,"status":59,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT01992380","A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects",[36],"2014-05-30","2013-11-13",24,[14],[69],{"trials":162,"activeCount":8},[163,172,181,192,201,211],{"nctId":164,"briefTitle":165,"status":59,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},"NCT03467477","Tau Screening Study in Subjects With Early Symptomatic AD",[37],"2018-11-15","2018-03-08",161,[17],[69],{"nctId":173,"briefTitle":174,"status":59,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT03322462","Tau Screening Study in Patients With Early Symptomatic AD",[37],"2018-08-31","2017-11-21",155,[17],[69],{"nctId":182,"briefTitle":183,"status":59,"phases":184,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT02079766","18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy",[37],"2015-10","2014-06",41,[189],"Chronic Traumatic Encephalopathy",[191,69],"florbetapir F 18",{"nctId":193,"briefTitle":194,"status":135,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":200},"NCT02051764","Imaging Characteristics of a Follow-up 18F-AV-1451 Scan",[37],"2016-12","2014-05",44,[14],[69,83],{"nctId":202,"briefTitle":203,"status":59,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT02278367","Clinical Evaluation of Flortaucipir F 18",[37],"2019-06-26","2014-12",179,[14,30,209],"Depression",[69],{"nctId":212,"briefTitle":213,"status":59,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":219},"NCT02795780","Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05",[37],"2017-08-28","2016-08",79,[14],[69],{"trials":221,"activeCount":8},[222,232,242],{"nctId":223,"briefTitle":224,"status":59,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT02516046","18F-AV-1451 Autopsy Study",[38],"2018-06-13","2018-07-15","2015-09",156,[14],[69],{"nctId":233,"briefTitle":234,"status":59,"phases":235,"primaryCompletion":236,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":240},"NCT03901105","Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease",[38],"2019-04-28","2019-03-28",205,[17],[241],"flortaucipir F18",{"nctId":243,"briefTitle":244,"status":59,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":250},"NCT02016560","Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects",[37,38],"2017-07-28","2013-12",383,[14],[191,69],{"trials":252,"activeCount":8},[],{"trials":254,"activeCount":8},[],{"intervention":256,"totalTrials":257,"cells":258},"18F-AV-133",4,{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":282,"PHASE3":295,"PHASE4":308,"NA":310},{"trials":260,"activeCount":8},[],{"trials":262,"activeCount":8},[263,272],{"nctId":264,"briefTitle":265,"status":59,"phases":266,"primaryCompletion":228,"completion":228,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT01710371","Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls",[36],"2012-12",40,[28],[256,271],"10% Arginine Hydrochloride-R-Gene 10",{"nctId":273,"briefTitle":274,"status":135,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":281},"NCT01515384","A Trial of 18F-AV-133 Positron Emission Tomography (PET)",[36],"2013-02","2010-06",19,[280,28],"Type 1 Diabetes",[256],{"trials":283,"activeCount":8},[284],{"nctId":285,"briefTitle":286,"status":59,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT01503944","A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)",[36,37],"2011-07","2010-03",30,[292,14,23],"Dementia With Lewy Bodies",[256,294],"18F-AV-45",{"trials":296,"activeCount":8},[297],{"nctId":298,"briefTitle":299,"status":59,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":307},"NCT01550484","A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders",[37,38],"2016-03","2012-04",170,[23,305,306],"Primary Parkinsonism","Lewy Body Parkinson's Disease",[256],{"trials":309,"activeCount":8},[],{"trials":311,"activeCount":8},[],{"intervention":313,"totalTrials":44,"cells":314},"flortaucipir F 18",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":332,"NA":334},{"trials":316,"activeCount":8},[],{"trials":318,"activeCount":8},[],{"trials":320,"activeCount":8},[],{"trials":322,"activeCount":8},[323],{"nctId":324,"briefTitle":325,"status":59,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT03901092","A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation",[38],"2019-04-26","2019-03-26",242,[17],[313],{"trials":333,"activeCount":8},[],{"trials":335,"activeCount":8},[],{"intervention":294,"totalTrials":44,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":339,"activeCount":8},[],{"trials":341,"activeCount":8},[],{"trials":343,"activeCount":8},[344],{"nctId":285,"briefTitle":286,"status":59,"phases":345,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":346,"interventions":347},[36,37],[292,14,23],[256,294],{"trials":349,"activeCount":8},[],{"trials":351,"activeCount":8},[],{"trials":353,"activeCount":8},[],{"intervention":355,"totalTrials":44,"cells":356},"[11C]-PIB",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":358,"activeCount":8},[],{"trials":360,"activeCount":8},[],{"trials":362,"activeCount":8},[363],{"nctId":364,"briefTitle":365,"status":59,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":371},"NCT00855868","Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals",[37],"2011-01","2009-03",28,[14],[191,355],{"trials":373,"activeCount":8},[],{"trials":375,"activeCount":8},[],{"trials":377,"activeCount":8},[],{"intervention":379,"totalTrials":44,"cells":380},"florbetapir 18F",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":382,"activeCount":8},[],{"trials":384,"activeCount":8},[],{"trials":386,"activeCount":8},[387],{"nctId":388,"briefTitle":389,"status":59,"phases":390,"primaryCompletion":267,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT01890343","Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",[37],"2013-04","2009-09",34,[14,32],[379,396],"18F-FDG",{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[],{"trials":402,"activeCount":8},[],{"intervention":396,"totalTrials":44,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":406,"activeCount":8},[],{"trials":408,"activeCount":8},[],{"trials":410,"activeCount":8},[411],{"nctId":388,"briefTitle":389,"status":59,"phases":412,"primaryCompletion":267,"completion":391,"start":392,"enrollment":393,"conditions":413,"interventions":414},[37],[14,32],[379,396],{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[],{"trials":420,"activeCount":8},[],{"intervention":271,"totalTrials":44,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":424,"activeCount":8},[],{"trials":426,"activeCount":8},[427],{"nctId":264,"briefTitle":265,"status":59,"phases":428,"primaryCompletion":228,"completion":228,"start":267,"enrollment":268,"conditions":429,"interventions":430},[36],[28],[256,271],{"trials":432,"activeCount":8},[],{"trials":434,"activeCount":8},[],{"trials":436,"activeCount":8},[],{"trials":438,"activeCount":8},[],{"intervention":440,"totalTrials":44,"cells":441},"18F-AV-1451",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":454,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":443,"activeCount":8},[],{"trials":445,"activeCount":8},[446],{"nctId":447,"briefTitle":448,"status":449,"phases":450,"primaryCompletion":451,"completion":451,"start":185,"enrollment":8,"conditions":452,"interventions":453},"NCT02512029","18F-AV-1451 PET Imaging in TBI","WITHDRAWN",[36],"2017-04",[30],[440],{"trials":455,"activeCount":8},[],{"trials":457,"activeCount":8},[],{"trials":459,"activeCount":8},[],{"trials":461,"activeCount":8},[],{"intervention":463,"totalTrials":44,"cells":464},"11C-PiB",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":466,"activeCount":8},[],{"trials":468,"activeCount":8},[469],{"nctId":470,"briefTitle":471,"status":59,"phases":472,"primaryCompletion":228,"completion":228,"start":61,"enrollment":129,"conditions":473,"interventions":474},"NCT02120664","Florbetapir Calibration to the Centiloid Scale",[36],[14],[475,463],"Florbetapir",{"trials":477,"activeCount":8},[],{"trials":479,"activeCount":8},[],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[],{"intervention":485,"totalTrials":44,"cells":486},"18F-LY3950321",{"EARLY_PHASE1":487,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":488,"activeCount":8},[489],{"nctId":490,"briefTitle":491,"status":59,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":21,"conditions":495,"interventions":498},"NCT05775601","18F-LY3950321-01 Biodistribution and Safety Study",[35],"2023-04-04","2023-02-28",[496,497],"Diagnostic Agent Adverse Reaction","Radiation Exposure",[485],{"trials":500,"activeCount":8},[],{"trials":502,"activeCount":8},[],{"trials":504,"activeCount":8},[],{"trials":506,"activeCount":8},[],{"trials":508,"activeCount":8},[],{"intervention":510,"totalTrials":44,"cells":511},"18F-LY3546117",{"EARLY_PHASE1":512,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":531,"NA":533},{"trials":513,"activeCount":8},[514],{"nctId":515,"briefTitle":516,"status":517,"phases":518,"primaryCompletion":519,"completion":519,"start":520,"enrollment":290,"conditions":521,"interventions":524},"NCT04721756","Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging","UNKNOWN",[35],"2024-04","2022-04-12",[522,523],"Neoplasms","Neoplasms Malignant",[510],{"trials":526,"activeCount":8},[],{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[],{"trials":532,"activeCount":8},[],{"trials":534,"activeCount":8},[],{"intervention":191,"totalTrials":536,"cells":537},21,{"EARLY_PHASE1":538,"PHASE1":553,"PHASE2":581,"PHASE3":631,"PHASE4":669,"NA":680},{"trials":539,"activeCount":8},[540,549],{"nctId":541,"briefTitle":542,"status":59,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":548},"NCT01565291","A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers",[35],"2008-01","2007-06",32,[17],[191],{"nctId":75,"briefTitle":76,"status":59,"phases":550,"primaryCompletion":78,"completion":78,"start":79,"enrollment":80,"conditions":551,"interventions":552},[35],[17],[69,83],{"trials":554,"activeCount":8},[555,564,573],{"nctId":556,"briefTitle":557,"status":59,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT01565330","A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers",[36],"2008-08","2008-03",20,[17],[191],{"nctId":565,"briefTitle":566,"status":59,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT01565343","A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers",[36],"2009-04","2008-04",25,[14],[191],{"nctId":574,"briefTitle":575,"status":59,"phases":576,"primaryCompletion":544,"completion":544,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT01564706","A Study of 18F-AV-45 in Healthy Volunteers",[36],"2007-10",9,[17],[191],{"trials":582,"activeCount":8},[583,587,597,606,610,618,627],{"nctId":364,"briefTitle":365,"status":59,"phases":584,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":585,"interventions":586},[37],[14],[191,355],{"nctId":588,"briefTitle":589,"status":59,"phases":590,"primaryCompletion":591,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT01518374","Clinical Evaluation of Florbetapir F 18 (18F-AV-45)",[37],"2017-05-03","2009-12",1768,[17,20,595],"Neurodegenerative Diseases",[83],{"nctId":598,"briefTitle":599,"status":59,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":605},"NCT00857506","Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)",[37],"2011-12","2009-01",152,[14,20],[191],{"nctId":182,"briefTitle":183,"status":59,"phases":607,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":608,"interventions":609},[37],[189],[191,69],{"nctId":611,"briefTitle":612,"status":59,"phases":613,"primaryCompletion":614,"completion":614,"start":602,"enrollment":615,"conditions":616,"interventions":617},"NCT00857532","Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients",[37],"2011-11",31,[23],[191],{"nctId":619,"briefTitle":620,"status":59,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT00702143","A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",[37],"2008-12","2008-06",184,[14,20],[191],{"nctId":193,"briefTitle":194,"status":135,"phases":628,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":629,"interventions":630},[37],[14],[69,83],{"trials":632,"activeCount":8},[633,642,646,654,662],{"nctId":634,"briefTitle":635,"status":59,"phases":636,"primaryCompletion":637,"completion":637,"start":288,"enrollment":638,"conditions":639,"interventions":641},"NCT01400425","Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline",[38],"2012-07",239,[640],"Progressive Cognitive Decline",[191],{"nctId":243,"briefTitle":244,"status":59,"phases":643,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":644,"interventions":645},[37,38],[14],[191,69],{"nctId":647,"briefTitle":648,"status":59,"phases":649,"primaryCompletion":289,"completion":650,"start":622,"enrollment":651,"conditions":652,"interventions":653},"NCT00857415","Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain",[38],"2010-05",226,[14],[191],{"nctId":655,"briefTitle":656,"status":59,"phases":657,"primaryCompletion":658,"completion":288,"start":289,"enrollment":659,"conditions":660,"interventions":661},"NCT01447719","Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07",[38],"2011-03",110,[14],[191],{"nctId":663,"briefTitle":664,"status":59,"phases":665,"primaryCompletion":666,"completion":666,"start":666,"enrollment":268,"conditions":667,"interventions":668},"NCT01565382","Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)",[38],"2011-02",[14],[191],{"trials":670,"activeCount":8},[671],{"nctId":672,"briefTitle":673,"status":59,"phases":674,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT02051790","Evaluation of Reader Training Processes",[39],"2014-08","2014-03",241,[14],[191],{"trials":681,"activeCount":8},[682,688,694],{"nctId":683,"briefTitle":684,"status":59,"phases":685,"primaryCompletion":367,"completion":367,"start":367,"enrollment":129,"conditions":686,"interventions":687},"NCT01565369","Evaluation of Physician Training Methods to Read Florbetapir-PET Scans",[40],[14],[191],{"nctId":689,"briefTitle":690,"status":59,"phases":691,"primaryCompletion":650,"completion":650,"start":289,"enrollment":187,"conditions":692,"interventions":693},"NCT01565356","Evaluation of PET Scan Timing Relative to AV-45 Injection Time",[40],[14],[191],{"nctId":695,"briefTitle":696,"status":59,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":702},"NCT01550549","Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans",[40],"2011-09","2011-08",151,[17,20,595],[191],{"intervention":704,"totalTrials":21,"cells":705},"florbetapir",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":723,"PHASE3":725,"PHASE4":735,"NA":751},{"trials":707,"activeCount":8},[],{"trials":709,"activeCount":8},[710,719],{"nctId":711,"briefTitle":712,"status":59,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":718},"NCT01660815","A Study of Florbetapir (18F) in Japanese Healthy Volunteers",[36],"2013-01","2012-08",7,[14],[704],{"nctId":470,"briefTitle":471,"status":59,"phases":720,"primaryCompletion":228,"completion":228,"start":61,"enrollment":129,"conditions":721,"interventions":722},[36],[14],[475,463],{"trials":724,"activeCount":8},[],{"trials":726,"activeCount":8},[727],{"nctId":728,"briefTitle":729,"status":59,"phases":730,"primaryCompletion":276,"completion":276,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT01662882","A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",[37,38],"2012-10",48,[14,20],[704],{"trials":736,"activeCount":8},[737,743],{"nctId":738,"briefTitle":739,"status":59,"phases":740,"primaryCompletion":197,"completion":197,"start":676,"enrollment":63,"conditions":741,"interventions":742},"NCT02107599","The Feasibility of Florbetapir Quantitation in Europe",[39],[14],[475],{"nctId":744,"briefTitle":745,"status":59,"phases":746,"primaryCompletion":747,"completion":747,"start":731,"enrollment":748,"conditions":749,"interventions":750},"NCT01703702","Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline",[39],"2015-04",641,[14],[704],{"trials":752,"activeCount":8},[753],{"nctId":754,"briefTitle":755,"status":449,"phases":756,"primaryCompletion":757,"completion":757,"start":99,"enrollment":8,"conditions":758,"interventions":759},"NCT02029547","Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians",[40],"2015-05",[14],[475],{"intervention":761,"totalTrials":44,"cells":762},"florbetapir F 18 PET scan",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":764,"activeCount":8},[],{"trials":766,"activeCount":8},[],{"trials":768,"activeCount":8},[],{"trials":770,"activeCount":8},[],{"trials":772,"activeCount":8},[],{"trials":774,"activeCount":8},[775],{"nctId":776,"briefTitle":777,"status":59,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT02918539","Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials",[],"2017-10-18","2016-10",317,[17,783],"Cognition Disorders",[761]]